Discover our new webpage dedicated to 90 years of HA
and download our White paper now!
Press releases
March 10, 2022
GelMEDIX
This partnership represents the first equity investment of the incubator created by HTL to accelerate the development of innovative treatments using biopolymers in therapeutic areas with unmet medical needs.
HTL will provide financial, industrial and scientific support to GelMEDIX to facilitate the development of next generation ocular and regenerative therapies based on its proprietary hydrogel platform.
This platform enables the delivery of therapeutics from small molecules to cell and gene therapies.
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Articles November 14, 2024Discover our new webpage dedicated to 90 years of HA and download our White Paper!
and download our White paper now!
-
Articles October 8, 2024HTL Biotechnology at CPHI Milano
As the leading global event for the pharmaceutical industry, CPHI Milan brought together key stakeholders from across the sector to foster connections and innovation.
-
Articles October 4, 20241st symposium for HTL Biotechnology at MAIS congress
As a key event for regenerative medicine and biotech innovation, the MAIS Congress in Marbella brought together leading professionals to explore the latest advancements in the field. A unique opportunity to share with the medical aesthetic community our biopolymers platform.